Metabotropic glutamate receptor 1 (mGluR1): Antibody specificity and receptor expression in cultured primary neurons

2012 ◽  
Vol 204 (2) ◽  
pp. 221-226 ◽  
Author(s):  
Ramses Ayala ◽  
Lauren R. Kett ◽  
Tiffany L. Leach ◽  
Anne B. Young ◽  
Anthone W. Dunah ◽  
...  
Keyword(s):  
Glutamate Receptor ◽  
Metabotropic Glutamate Receptor ◽  
Receptor Expression ◽  
Antibody Specificity ◽  
Primary Neurons ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1

scholarly journals Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Anna E. M. Bastiaansen ◽  
A. Mieke Timmermans ◽  
Marcel Smid ◽  
Carolien H. M. van Deurzen ◽  
Esther S. P. Hulsenboom ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Protein Expression ◽  
Glutamate Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Metabotropic Glutamate Receptor ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1 ◽  
Novel Target ◽  
Cancer Tissues

AbstractNew therapies are an urgent medical need in all breast cancer subgroups. Metabotropic glutamate receptor 1 (mGluR1) is suggested as a potential new molecular target. We examined the prevalence mGluR1 expression in different clinically relevant breast cancer subgroups and determined its association with prognosis. In this retrospective cohort, 394 consecutive primary breast cancer tissues were incorporated into a tissue microarray and immunohistochemically stained for mGluR1. The prevalence of mGluR1 protein expression in different breast cancer subgroups was evaluated and correlated with metastasis-free survival (MFS) and overall survival (OS). In total, 56% (n = 219) breast cancer tissues had mGluR1 expression. In estrogen receptor (ER)-negative tumors, 31% (n = 18/58) had mGluR1 expression that was significantly associated with MFS (HR 5.00, 95% CI 1.03–24.35, p = 0.046) in multivariate analysis, independently from other prognostic factors. Of the 44 triple-negative breast cancer (TNBC), 25% (n = 11) expressed mGluR1. mGluR1 expression in TNBC was significantly associated with shorter MFS (HR 8.60, 95% CI 1.06–20.39, p = 0.044) and with poor OS (HR 16.07, 95% CI 1.16–223.10, p = 0.039). In conclusion, mGluR1 is frequently expressed in breast cancer. In ER-negative breast cancer and in TNBC mGluR1 protein expression is an unfavorable prognostic marker. This study provides rationale to explore mGluR1 as a novel target for breast cancer treatment, especially for the more aggressive TNBC.

scholarly journals Autosomal-Recessive Congenital Cerebellar Ataxia Is Caused by Mutations in Metabotropic Glutamate Receptor 1

2012 ◽  
Vol 91 (3) ◽  
pp. 553-564 ◽  
Author(s):  
Velina Guergueltcheva ◽  
Dimitar N. Azmanov ◽  
Dora Angelicheva ◽  
Katherine R. Smith ◽  
Teodora Chamova ◽  
...  
Keyword(s):  
Cerebellar Ataxia ◽  
Glutamate Receptor ◽  
Autosomal Recessive ◽  
Metabotropic Glutamate Receptor ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1

scholarly journals Metabotropic Glutamate Receptor-1 Contributes to Progression in Triple Negative Breast Cancer

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e81126 ◽  
Author(s):  
Malathi Banda ◽  
Cecilia L. Speyer ◽  
Sara N. Semma ◽  
Kingsley O. Osuala ◽  
Nicole Kounalakis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Glutamate Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Metabotropic Glutamate Receptor ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1
Sign in / Sign up

Export Citation Format

Share Document